Full history for every metric is available with a Kvantra account

Stock profile

Catalent, Inc. (CTLT)

Country: United States of AmericaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: NYSE

Delisted · last close 17 Dec 2024

Current price
63.48 USD0.00%
Last close 17 Dec 2024
Benchmarks

Key financial summary

Financials in USD
201920202021202220232024TTM
Total revenue$m2,5183,0943,9984,8284,2764,3814,422
Operating profit$m-749-
Net profit$m137173585499-232-1,043-413
EPS reported$-5.76-2.26
Operating cashflow per share$1.481.48
Capex per share$1.811.81
FCF per share$-0.33-0.33
Free cash flow$m-5999
Net debt$m4,3044,599
Book value equity$m3,6043,542
Book value per share$19.9119.46
Number of sharesm181182
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
201920202021202220232024TTM
Value
P/E TTMx--
P/B LTMx2.823.25
P/S LTMx2.322.61
P/FCF LTMx-172.29116.39
EV/EBITDA LTMx-52.3440.40
EV/Sales LTMx3.393.65
Earnings Yield LTM%-10.26%-9.08%
FCF Yield%-0.58%0.86%
Quality
ROE%-28.94%-25.32%
ROIC%-8.53%-8.53%
Operating margin%-17.10%-17.10%
Gross margin%21.75%21.75%
FCF/Sales%-1.35%-1.35%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%+2.46%+4.39%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx-0.010.02
Net Debt/EBITDAx-16.55-16.55
EBIT/Net interestx-2.95-2.95
Net debt/market cap%42.34%39.91%
Net debt/Equityx1.191.30
Gross debt/equityx1.381.40

Company overview

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

WebsiteN/A
IndustryDrug Manufacturers - Specialty & Generic
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 17 Dec 2024

Catalent, Inc. (CTLT)

CTLT · NYSE · Healthcare
63.48 USD0.00%
Benchmarks
Financialsin USD
20232024TTM
About

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

IndustryDrug Manufacturers - Specialty & Generic
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free